Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Circumstantial treatment de-escalation in early breast cancer

Elzbieta Senkus-Konefka • 14 Mar 2025
BCC 2025
Breast Cancer

Elżbieta Senkus-Konefka, MD, PhD, Medical University of Gdańsk, Gdańsk, Poland, discusses controversies in early breast cancer care around excessive escalation in the treatment of early breast cancer. When a treatment significantly affects quality of life and toxicity, the standard of care should emphasise de-escalation. Current data is contraindicatory, outlining the requirement for regulated parameters. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elzbieta Senkus-Konefka

Integrating precision oncology into MDT decision-making
1:51
Integrating precision oncology into MDT decision-making
Elzbieta Senkus-Konefka • 14 Mar 2025
Multidisciplinary decision-making in breast cancer
1:57
Multidisciplinary decision-making in breast cancer
Elzbieta Senkus-Konefka • 14 Mar 2025
What have we learned from recent clinical trials in early breast cancer treatment?
4:13
What have we learned from recent clinical trials in early breast cancer treatment?
Elzbieta Senkus-Konefka • 21 Sep 2017
The importance of the OlympiA trial for breast cancer patients
2:18
The importance of the OlympiA trial for breast cancer patients
Elzbieta Senkus-Konefka • 21 Sep 2017

Related Videos

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
The content of VJOncology is intended for healthcare professionals